WO2003046566A2 - Marqueurs biopolymeres pedf predictifs de la maladie d'alzheimer - Google Patents

Marqueurs biopolymeres pedf predictifs de la maladie d'alzheimer Download PDF

Info

Publication number
WO2003046566A2
WO2003046566A2 PCT/CA2002/001641 CA0201641W WO03046566A2 WO 2003046566 A2 WO2003046566 A2 WO 2003046566A2 CA 0201641 W CA0201641 W CA 0201641W WO 03046566 A2 WO03046566 A2 WO 03046566A2
Authority
WO
WIPO (PCT)
Prior art keywords
biopolymer
sample
disease
disease state
analyte
Prior art date
Application number
PCT/CA2002/001641
Other languages
English (en)
Other versions
WO2003046566A3 (fr
Inventor
George Jackowski
John Marshall
Original Assignee
Syn.X Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syn.X Pharma, Inc. filed Critical Syn.X Pharma, Inc.
Priority to AU2002335965A priority Critical patent/AU2002335965A1/en
Priority to JP2003547954A priority patent/JP2005510722A/ja
Publication of WO2003046566A2 publication Critical patent/WO2003046566A2/fr
Publication of WO2003046566A3 publication Critical patent/WO2003046566A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne l'utilisation d'une combinaison d'étapes préparatoires conjointement avec une spectroscopie de masse et des opérations de détection de temps de vol en vue d'augmenter la diversité de biopolymères identifiables dans un échantillon particulier. Le groupe de biopolymères identifiés dans cet échantillon est alors visualisé en fonction de leur capacité à démontrer au moins un état pathologique particulier, ce qui confère à un diagnosticien la possibilité de déterminer la présence ou l'absence de cet état pathologique selon la présence et/ou l'absence dudit biopolymère, de prédire une évaluation du risque de maladie, et de développer des moyens thérapeutiques contre cette maladie.
PCT/CA2002/001641 2001-11-23 2002-10-31 Marqueurs biopolymeres pedf predictifs de la maladie d'alzheimer WO2003046566A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002335965A AU2002335965A1 (en) 2001-11-23 2002-10-31 Pedf biopolymer markers predictive of alzheimers disease
JP2003547954A JP2005510722A (ja) 2001-11-23 2002-10-31 アルツハイマー病を予測するｐｅｄｆバイオポリマーマーカー

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99336801A 2001-11-23 2001-11-23
US09/993,368 2001-11-23

Publications (2)

Publication Number Publication Date
WO2003046566A2 true WO2003046566A2 (fr) 2003-06-05
WO2003046566A3 WO2003046566A3 (fr) 2003-09-04

Family

ID=25539457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001641 WO2003046566A2 (fr) 2001-11-23 2002-10-31 Marqueurs biopolymeres pedf predictifs de la maladie d'alzheimer

Country Status (3)

Country Link
JP (1) JP2005510722A (fr)
AU (1) AU2002335965A1 (fr)
WO (1) WO2003046566A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201322094D0 (en) * 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005422A2 (fr) * 1999-07-15 2001-01-25 Biomerieux Stelhys Utilisation d'un polypeptique pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique autoimmune
WO2001075454A2 (fr) * 2000-04-03 2001-10-11 Oxford Glycosciences (Uk) Ltd. Molecules d'acides nucleiques, polypeptides et leurs utilisations pour diagnostic et le traitement de la maladie d'alzheimer notamment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005422A2 (fr) * 1999-07-15 2001-01-25 Biomerieux Stelhys Utilisation d'un polypeptique pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique autoimmune
WO2001075454A2 (fr) * 2000-04-03 2001-10-11 Oxford Glycosciences (Uk) Ltd. Molecules d'acides nucleiques, polypeptides et leurs utilisations pour diagnostic et le traitement de la maladie d'alzheimer notamment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BECERRA S PATRICIA ET AL: "Pigment Epithelium-derived Factor Behaves Like a Noninhibitory Serpin: Neurotrophic activity does not require the serpin reactive loop." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 43, 1995, pages 25992-25999, XP001153115 ISSN: 0021-9258 *
JIN J ET AL: "Detection of PEDF in Normal Human Conjunctiva but not in Pterygia." ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol. 2002, 2002, page Abstract No. 127 XP001153017 Annual Meeting of the Association For Research in Vision and Ophthalmology;Fort Lauderdale, Florida, USA; May 05-10, 2002 *
KIM S Y ET AL: "Expression of Pigment Epithelium-Derived Factor (PEDF) in the Human Retina and Choroid." ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol. 2002, 2002, page Abstract No. 2755 XP001153018 Annual Meeting of the Association For Research in Vision and Ophthalmology;Fort Lauderdale, Florida, USA; May 05-10, 2002 *
STEELE F R ET AL: "PIGMENT EPITHELIUM-DERIVED FACTOR: NEUROTROPHIC ACTIVITY AND IDENTIFICATION AS A MEMBER OF THE SERINE PROTEASE INHIBITOR GENE FAMILY" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 90, 1 February 1993 (1993-02-01), pages 1526-1530, XP000606398 ISSN: 0027-8424 *

Also Published As

Publication number Publication date
JP2005510722A (ja) 2005-04-21
AU2002335965A1 (en) 2003-06-10
WO2003046566A3 (fr) 2003-09-04

Similar Documents

Publication Publication Date Title
US20060205091A1 (en) Protein biopolymer markers predictive of insulin resistance
US20060160233A1 (en) Ig heavy chain, ig kappa, ig lambda biopolymer markers predictive of alzheimers disease
US20060275831A1 (en) Complement C3 precursor biopolymer markers predictive of type II diabetes
US20060211146A1 (en) Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance
US20060211143A1 (en) Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance
US20030100011A1 (en) IG lambda biopolymer markers predictive of alzheimers disease
US20030100010A1 (en) Fibrinogen biopolymer Marker predictive of type II diabetes
US20030100016A1 (en) Complement C3 precursor biopolymer markers predictive of Alzheimers disease
WO2003046004A2 (fr) Marqueurs biopolymeres de macroglobuline indicateurs d'une resistance a l'insuline
US20070031979A1 (en) Protein biopolymer markers predictive of type II diabetes
US20060211148A1 (en) Protein biopolymer markers indicative of age matched control
US20090093000A1 (en) Glycoprotein and apolipoprotein biopolymer markers predictive of Alzheimers disease
WO2003046571A2 (fr) Marqueurs biopolymeres de hp et d'apolipoproteines predictifs de la maladie d'alzheimer
US20030100014A1 (en) Apolipoprotein biopolymer markers predictive of type II diabetes
WO2003054014A2 (fr) Marqueurs biopolymeres d'apolipoproteine indiquant la maladie d'alzheimer
WO2003046557A2 (fr) Marqueurs de biopolymeres hp predictifs d'une resistance a l'insuline
WO2003046569A1 (fr) Marqueur biopolymere de precurseur de fibronectine predictif de la maladie d'alzheimer
US20030100009A1 (en) Inter alpha trypsin inhibitor biopolymer markers indicative of insulin resistance
US20060024761A1 (en) Protein biopolymer markers predictive of alzheimer's disease
US20060194338A1 (en) Complement c3 precursor biopolymer markers indicative of insulin resistance
US20030100012A1 (en) Plasma protease C1 biopolymer markers predictive of alzheimers disease
WO2003046566A2 (fr) Marqueurs biopolymeres pedf predictifs de la maladie d'alzheimer
WO2003046564A2 (fr) Marqueurs biopolymeres proteiques predictifs de la maladie d'alzheimer
WO2003046000A2 (fr) Marqueurs biopolymeres d'apolipoproteine predicitifs d'une resistance a l'insuline
WO2003046556A2 (fr) Marqueurs biopolymeres de globine indicateurs de l'insulinoresistance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003547954

Country of ref document: JP

122 Ep: pct application non-entry in european phase